Development of machine learning-based clinical decision support system for hepatocellular carcinoma
Gwang Hyeon Choi1, Jihye Yun2, Jonggi Choi1
1Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Scientific Reports
|September 10, 2020
Summary
A new machine learning system aids hepatocellular carcinoma (HCC) treatment decisions, outperforming current guidelines. This clinical decision support system (CDSS) accurately recommends initial therapies and predicts patient survival.
Area of Science:
- Hepatobiliary Medicine
- Oncology
- Medical Informatics
Background:
- Current Barcelona Clinic Liver Cancer (BCLC) staging system recommendations for hepatocellular carcinoma (HCC) treatment often mismatch actual clinical choices.
- Hepatocellular carcinoma (HCC) treatment decisions require accurate staging and personalized recommendations.
Purpose of the Study:
- To develop and validate a machine learning-based clinical decision support system (CDSS) for recommending initial treatment options for HCC.
- To predict overall survival (OS) in HCC patients using the developed CDSS.
Main Methods:
- Retrospective analysis of 1,021 HCC patients' hospital records, collecting 61 pretreatment variables.
- Development of a six-step multi-classifier random forest model for treatment recommendation and seven survival prediction models.
- Validation of the CDSS using a derivation set (N=813) and a validation set (N=208).
Main Results:
- The HCC-CDSS demonstrated good performance in treatment recommendation accuracy: 81.0% for radiofrequency ablation (RFA) or resection vs. not, 88.4% for RFA vs. resection, and 76.8% for transarterial chemoembolization (TACE) vs. not.
- The system effectively predicted overall survival (OS) for various treatment options.
- Key pretreatment variables were identified and utilized in the model.
Conclusions:
- The developed HCC-CDSS shows strong performance in guiding initial treatment decisions for hepatocellular carcinoma.
- This AI-driven tool can serve as a valuable aid for clinicians in optimizing HCC management.
- The CDSS offers a data-driven approach to personalize HCC treatment and improve patient outcomes.
